Related coverage linked through entity extraction aliases.
Jul 10, 2026
AI is transforming cardiovascular medicine: $1.4B+ in investments, a new cardiac biomarker sensor, and stroke-imaging software in 2,500+ hospitals. FDA, EMA, and PMDA are opening clearer regulatory pathways.
Jul 06, 2026
Hematologic cancer survivors face elevated CVD risk and fourfold higher heart failure risk. Cardiac screening is low among cardiotoxic treatment recipients. A trial found simple risk assessment may suffice.
Jul 14, 2026
Cardiol Therapeutics announced the publication of its Phase II MAvERIC study results in the Journal of the American Heart Association. The study showed CardiolRx led to rapid and sustained reductions in pericarditis pain and inflammation with a favorable safety profile. The findings support the ongoing Phase III MAVERIC trial.
Jun 24, 2026
Multiple new studies highlight key factors affecting children's health and development. Research shows maternal cardiovascular health during pregnancy significantly impacts child developmental delays, with poor heart health increasing risk by 62%. A separate study found family finances and neighborhood opportunities account for about 16% of variability in children's brain function, while parental concern about illness proved highly accurate for detecting serious conditions in children.
Mar 22, 2026
Prothena reported Q4 and full year 2025 financial results with $308.4 million in cash as partners Roche and Novo Nordisk initiated Phase 3 trials for prasinezumab and coramitug, both expected to complete in 2029.
Mar 09, 2026
Three new CRISPR-based therapies show promise for treating heart failure through mitochondrial enhancement, cystic fibrosis via lipid nanoparticle gene insertion, and elevated cholesterol with single-dose gene editing targeting ANGPTL3.
